AFP is indicative of a biologically distinct subtype of HCC, often associated with poor prognosis and more stem‐cell‐like features (such as Epithelial Cell Adhesion Molecule [Ep‐CAM] expression), increased vascular endothelial growth factor (VEGF) pathway activity, and increased activity of VEGFR2‐targeted antibodies in preclinical models [33, 34]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.